Aarkstore - Interleukin-2 (IL-2) Inhibitors -Pipeline Insights, 2014

1
Interleukin-2 (IL-2) Inhibitors -Pipeline
Insights, 2014
Category Pharmaceuticals Healthcare

• Browse Complete Report -
• http//www.aarkstore.com/pharmaceuticals-healthcar
  e/75779/interleukin-2-il-2-inhibitors-pipeline-ins
  ights-2014

2
Summary

• DelveInsights,Interleukin-2 (IL-2)
  Inhibitors-Pipeline Insights, 2014, report
  provides comprehensive insights about pipeline
  drugs across this mechanism of action (MOA). A
  key objective of the report is to establish the
  understanding for all the pipeline drugs that
  fall under Interleukin-2 (IL-2) Inhibitors. This
  report provides information on the therapeutic
  development based on the Interleukin-2 (IL-2)
  Inhibitors dealing with mechanism of action,
  comparative analysis at various stages covering
  Filed, Phase III, Phase II, Phase I, IND filed,
  Preclinical, Discovery and unknown stages,
  therapeutics assessment by monotherapy and
  combination products and molecule type drug
  information. The report also covers the companies
  information involved in the therapeutic
  development of the products. It also has
  highlighted the discontinued and dormant products.

3
Summary

• Data Sources
• The report is built using data and information
  sourced from proprietary databases, primary and
  secondary research and in-house analysis by
  DelveInsight team of industry experts.Secondary
  sources information and data has been collected
  from various printable and non-printable sources
  like search engines, News websites, Government
  Websites, Trade Journals, White papers,
  Magazines, Trade associations, Books, Industry
  Portals, Industry Associations and access to
  available databases.Please note this report
  requires certain updates. We have all the
  information available but require 3 business days
  to complete the process and ensure it is as
  up-to-date as possible. Certain sections in the
  report may be removed or altered based on the
  availability and relevance of data for the
  indicated mechanism of action. 

4
Summary

• Scope 
• The report provides a snapshot of the global
  therapeutic landscape of Interleukin-2 (IL-2)
  InhibitorsThe report provides pipeline products
  under drug profile section which includes product
  description, MOA, licensors collaborators,
  development partner and chemical
  informationCoverage of the Interleukin-2 (IL-2)
  Inhibitors pipeline on the basis of target, MOA,
  route of administration, technology involved and
  molecule typeThe report reviews key players
  involved in the therapeutics development for
  Interleukin-2 (IL-2) Inhibitors and also provide
  company profilingThe report also gives the
  information of dormant and discontinued pipeline
  projects Pipeline products coverage based on
  various stages of development ranging from
  preregistration till discovery and undisclosed
  stages Provides pipeline assessment by
  monotherapy and combination therapy products,
  stage of development and molecule type

5
Summary

• Reasons to buyComplete MOA intelligence and
  complete understanding over therapeutics
  development for Interleukin-2 (IL-2)
  InhibitorsIdentify the relationship between the
  drugs and use it for target finding, drug
  repurposing, and precision medicine.Devise
  corrective measures for pipeline projects by
  understanding Interleukin-2 (IL-2) Inhibitors
  pipeline depth and focus of Indication
  therapeutics Developing strategic initiatives to
  support your drug development activities.Optimize
  your portfolio and keep you in touch with the
  rapidly changing pharmaceutical markets, and make
  the best decisions for your business.

6
Summary

• Develop and design in licensing and out licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and ScopeProvides
  strategically significant competitor information,
  analysis, and insights to formulate effective RD
  development strategies Modify the therapeutic
  portfolio by identifying discontinued projects
  and understanding the factors that drove them
  from pipelineGaining a Full Picture of the
  Competitive Landscape for Evidence based
  Decisions
• You can order full Report with TOC and for Sample
  page visit _at_
• http//www.aarkstore.com/pharmaceuticals-healthca
  re/75779/interleukin-2-il-2-inhibitors-pipeline-in
  sights-2014

7
Table of Content

• Interleukin-2 (IL-2) Inhibitors
  OverviewInterleukin-2 (IL-2) Inhibitors Disease
  AssociatedInterleukin-2 (IL-2) Inhibitors
  Pipeline TherapeuticsInterleukin-2 (IL-2)
  Inhibitors Therapeutics under Development by
  Companies Interleukin-2 (IL-2) Inhibitors Late
  Stage Products (Filed and Phase III)Comparative
  Analysis Interleukin-2 (IL-2) Inhibitors Mid
  Clinical Stage Products (Phase II)Comparative
  Analysis Interleukin-2 (IL-2) Inhibitors Early
  Clinical Stage Products (Phase I and IND
  Filed)Comparative Analysis Interleukin-2 (IL-2)
  Inhibitors Discovery and Pre-Clinical Stage
  Products Comparative Analysis Drug Candidate
  Profiles

8
Table of Content

• Interleukin-2 (IL-2) Inhibitors Therapeutics
  Assessment Assessment by Monotherapy
  Products Assessment by Combination
  Products Assessment by Route of
  Administration Assessment by Molecule
  Type Interleukin-2 (IL-2) Inhibitors
  Discontinued Products Interleukin-2 (IL-2)
  Inhibitors Dormant ProductsCompanies Involved in
  Therapeutics Development for Interleukin-2 (IL-2)
  Inhibitors Appendix Methodology Contact
  Us Disclaimer

9
List of Tables

• Number of Products under Development for
  Interleukin-2 (IL-2) Inhibitors by Therapy Area,
  2014Number of Products under Development for
  Interleukin-2 (IL-2) Inhibitors, 2014Number of
  Products under Development by Companies Comparati
  ve Analysis by Late Clinical Stage Products
  (Filed and Phase III), 2014Comparative Analysis
  Mid Clinical Stage Products (Phase II),
  2014Comparative Analysis Early Clinical Stage
  Products (Phase I and IND Filed),
  2014Comparative Analysis Discovery and
  Pre-Clinical Stage Products, 2014Drug Candidates
  Profiles

10
List of Tables

• Interleukin-2 (IL-2) Inhibitors Assessment by
  Monotherapy Products Interleukin-2 (IL-2)
  Inhibitors Assessment by Combination
  Products Interleukin-2 (IL-2) Inhibitors
  Assessment by Route of Administration Interleukin
  -2 (IL-2) Inhibitors Assessment by Stage and
  Route of Administration Interleukin-2 (IL-2)
  Inhibitors Assessment by Molecule
  Type Interleukin-2 (IL-2) Inhibitors Assessment
  by Stage and Molecule Type Interleukin-2 (IL-2)
  Inhibitors Therapeutics Discontinued
  Products Interleukin-2 (IL-2) Inhibitors
  Therapeutics Dormant ProductsProducts under
  Development by Companies, 2014

11
List of Figures

• Number of Products under Development for
  Interleukin-2 (IL-2) Inhibitors by Therapy Area,
  2014Number of Products under Development for
  Interleukin-2 (IL-2) Inhibitors, 2014Late
  Clinical Stage Products (Filed and Phase III),
  2014Mid Clinical Stage Products (Phase II),
  2014Early Clinical Stage Products (Phase I and
  IND Filed), 2014Discovery and Pre-Clinical Stage
  Products, 2014Interleukin-2 (IL-2) Inhibitors
  Assessment by Monotherapy Products Interleukin-2
  (IL-2) Inhibitors Assessment by Combination
  Products Interleukin-2 (IL-2) Inhibitors
  Assessment by Route of Administration Interleukin
  -2 (IL-2) Inhibitors Assessment by Stage and
  Route of Administration Interleukin-2 (IL-2)
  Inhibitors Assessment by Molecule
  Type Interleukin-2 (IL-2) Inhibitors Assessment
  by Stage and Molecule Type

12
Related Reports

• 2015 Worldwide Medical Laboratories
  Industry-Industry Market Report
• 2015 Worldwide Pharmaceutical Preparation Mfg.
  Industry-Industry Market Report
• OncoPlex Diagnostics - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• MetaStat, Inc. - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Advanced Cell Diagnostics, Inc. - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• Ascension Health - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Accretive Health, Inc. (ACHI) - Strategic SWOT
  Analysis Review
• Jazz Pharmaceuticals plc (JAZZ) - Financial and
  Strategic SWOT Analysis Review
• Pharmstandard (PHST) - Financial and Strategic
  SWOT Analysis Review
• GLG Life Tech Corporation (GLG) - Financial and
  Strategic SWOT Analysis Review

13

• Interleukin-2 (IL-2) Inhibitors -Pipeline
  Insights, 2014
• Published Dec. 2014 60 Pages
• DelveInsights,Interleukin-2 (IL-2)
  Inhibitors-Pipeline Insights, 2014, report
  provides comprehensive insights about pipeline
  drugs across this mechanism of action (MOA).
  
  Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news